Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $35.78 Consensus Target Price from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $38.8889.

Several research firms have recently commented on AGIO. HC Wainwright increased their price target on shares of Agios Pharmaceuticals from $48.00 to $62.00 and gave the company a “buy” rating in a research note on Wednesday. Truist Financial upped their price objective on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday. Zacks Research raised Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 4th. Bank of America boosted their target price on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, December 22nd.

Agios Pharmaceuticals Stock Down 3.9%

Agios Pharmaceuticals stock opened at $28.02 on Friday. The stock has a 50-day simple moving average of $33.74 and a 200 day simple moving average of $36.23. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -4.00 and a beta of 0.87. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm had revenue of $12.88 million for the quarter, compared to analyst estimates of $10.49 million. During the same quarter in the prior year, the firm earned $16.22 EPS. The company’s revenue was up 43.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Activity

In other news, insider Sarah Gheuens sold 3,302 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the sale, the insider owned 61,727 shares in the company, valued at $2,711,049.84. The trade was a 5.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 3,902 shares of company stock valued at $170,754. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors have recently bought and sold shares of AGIO. Bellevue Group AG raised its position in shares of Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after acquiring an additional 124,586 shares during the last quarter. Erste Asset Management GmbH increased its holdings in Agios Pharmaceuticals by 18.8% in the third quarter. Erste Asset Management GmbH now owns 2,764,900 shares of the biopharmaceutical company’s stock valued at $108,578,000 after purchasing an additional 438,411 shares during the last quarter. Wellington Management Group LLP increased its holdings in Agios Pharmaceuticals by 485.5% in the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after purchasing an additional 2,049,287 shares during the last quarter. Commodore Capital LP lifted its stake in Agios Pharmaceuticals by 0.6% in the third quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock valued at $93,859,000 after buying an additional 13,287 shares during the period. Finally, TCG Crossover Management LLC boosted its holdings in Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after buying an additional 733,038 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.